These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
928 related articles for article (PubMed ID: 33522752)
1. Humoral response to COVID-19 infection in immunosuppressed patients with inflammatory bowel disease. Scharrer S; Kutschera M; Weseslindtner L; Primas C; Vogelsang H Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):443-447. PubMed ID: 33522752 [TBL] [Abstract][Full Text] [Related]
2. Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease. Caldera F; Misch EA; Saha S; Wald A; Zhang Y; Hubers J; Megna B; Ley D; Reichelderfer M; Hayney MS Dig Dis Sci; 2019 Jan; 64(1):189-195. PubMed ID: 30317494 [TBL] [Abstract][Full Text] [Related]
3. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942 [TBL] [Abstract][Full Text] [Related]
4. Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study. Moradi G; Mohamadi Bolbanabad A; Ahmadi S; Aghaei A; Bahrami F; Veysi A; Nasiri Kalmarzi R; Shokri A; Ghaderi E; Mohsenpour B; Mohammadi A Int Immunopharmacol; 2021 Sep; 98():107893. PubMed ID: 34174700 [TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. Burke KE; Kochar B; Allegretti JR; Winter RW; Lochhead P; Khalili H; Colizzo FP; Hamilton MJ; Chan WW; Ananthakrishnan AN Inflamm Bowel Dis; 2021 Jan; 27(2):155-161. PubMed ID: 33089863 [TBL] [Abstract][Full Text] [Related]
7. Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type. Jørgensen KK; Høivik ML; Chopra A; Benth JŠ; Ricanek P; Moum PB; Jyssum I; Bolstad N; Warren DJ; Vaage PJT; Munthe PLA; Lundin PKEA; Anisdahl K; Syversen SW; Goll GL; Lund-Johansen F; Medhus AW; Jahnsen PJ Scand J Gastroenterol; 2023; 58(8):874-882. PubMed ID: 36788656 [TBL] [Abstract][Full Text] [Related]
8. COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States. Hadi YB; Thakkar S; Shah-Khan SM; Hutson W; Sarwari A; Singh S Gastroenterology; 2021 Oct; 161(4):1336-1339.e3. PubMed ID: 34144044 [No Abstract] [Full Text] [Related]
9. Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease. Potdar AA; Dube S; Naito T; Li K; Botwin G; Haritunians T; Li D; Casero D; Yang S; Bilsborough J; Perrigoue JG; Denson LA; Daly M; Targan SR; Fleshner P; Braun J; Kugathasan S; Stappenbeck TS; McGovern DPB Gastroenterology; 2021 Feb; 160(3):809-822.e7. PubMed ID: 33160965 [TBL] [Abstract][Full Text] [Related]
10. Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease on Biological Agents During the SARS-CoV-2 Pandemic. Iborra I; Puig M; Marín L; Calafat M; Cañete F; Quiñones C; González-González L; Cardona G; Mañosa M; Domènech E Dig Dis Sci; 2021 Dec; 66(12):4191-4196. PubMed ID: 33469807 [TBL] [Abstract][Full Text] [Related]
11. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak. Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201 [TBL] [Abstract][Full Text] [Related]
12. Serological evaluation of patients with coronavirus disease-2019 in Daegu, South Korea. Park S; Chang SH; Lee JH; Lee JH; Ham JY; Kim YK; Kim SG; Ryoo NH PLoS One; 2022; 17(1):e0262820. PubMed ID: 35051239 [TBL] [Abstract][Full Text] [Related]
13. Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection. Wang H; Yuan Y; Xiao M; Chen L; Zhao Y; Haiwei Zhang ; Long P; Zhou Y; Xu X; Lei Y; Bihao Wu ; Diao T; Cai H; Liu L; Shao Z; Wang J; Bai Y; Wang K; Peng M; Liu L; Han S; Mei F; Cai K; Lei Y; Pan A; Wang C; Gong R; Li X; Wu T Cell Mol Immunol; 2021 Jul; 18(7):1832-1834. PubMed ID: 34099890 [No Abstract] [Full Text] [Related]
14. A Longitudinal, 3-Month Serologic Assessment of SARS-CoV-2 Infections in a Belgian Hemodialysis Facility. Labriola L; Scohy A; Seghers F; Perlot Q; De Greef J; Desmet C; Romain C; Morelle J; Yombi JC; Kabamba B; Rodriguez-Villalobos H; Jadoul M Clin J Am Soc Nephrol; 2021 Apr; 16(4):613-614. PubMed ID: 33208402 [No Abstract] [Full Text] [Related]
15. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects. Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828 [TBL] [Abstract][Full Text] [Related]
16. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients. Wang B; Wang L; Kong X; Geng J; Xiao D; Ma C; Jiang XM; Wang PH J Med Virol; 2020 Sep; 92(9):1684-1689. PubMed ID: 32343415 [TBL] [Abstract][Full Text] [Related]
17. Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. Yang HS; Racine-Brzostek SE; Karbaschi M; Yee J; Dillard A; Steel PAD; Lee WT; McDonough KA; Qiu Y; Ketas TJ; Francomano E; Klasse PJ; Hatem L; Westblade L; Wu H; Chen H; Zuk R; Tan H; Girardin RC; Dupuis AP; Payne AF; Moore JP; Cushing MM; Chadburn A; Zhao Z Biosens Bioelectron; 2021 Apr; 178():113008. PubMed ID: 33515984 [TBL] [Abstract][Full Text] [Related]
18. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study. Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW; Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432 [TBL] [Abstract][Full Text] [Related]
19. IgG Antibodies, SARS-CoV-2 Load, and Prognostic Indicators in Patients with Severe and Mild COVID-19 in Japan. Kashiwagi K; Maeda T; Yoshizawa S; Sato T; Aoki K; Ishii Y; Tateda K J Nippon Med Sch; 2021 Sep; 88(4):380-383. PubMed ID: 33250476 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of Anti-SARS-CoV-2 Specific Antibodies in Health-Care Workers Compared to General Population during an Early Phase of the Pandemic, Tehran-Iran. Mortezagholi S; Rostamzadeh D; Alinejad M; Younesi V; Tabarsi P; Shabani M Iran J Immunol; 2021 Mar; 18(1):82-92. PubMed ID: 33787517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]